Healthcare [ 13/13 ] | Biotechnology [ 106/161 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 9, 23 | -1.29 Increased by +7.79% | - |
| Aug 15, 23 | -0.7 Decreased by -139.08% | - |
| May 15, 23 | -1.27 Decreased by -227.09% | - |
| Mar 31, 23 | -10.89 Decreased by -1.19 K% | -0.11 Decreased by -9.8 K% |
| Nov 10, 22 | -1.4 Increased by +36.36% | 0.2 Decreased by -800% |
| Aug 9, 22 | 1.8 Increased by +1.16 K% | -2.6 Increased by +169.23% |
| May 16, 22 | 1 Increased by +233.33% | -2.6 Increased by +138.46% |
| Mar 31, 22 | 1 Increased by +272.56% | -2.6 Increased by +138.46% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -10.27 M Increased by +73.62% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -3.68 M Decreased by -135.38% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -4.73 M Decreased by -169.5% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -21.74 M Decreased by -2.2 K% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -38.92 M Decreased by -312.71% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | 10.4 M Increased by +652.94% | Increased by +N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | 6.81 M Increased by +142.03% | Increased by +N/A% Decreased by N/A% |
| Dec 31, 21 | 0 Decreased by N/A% | 1.04 M Increased by +287.54% | Increased by +N/A% Decreased by N/A% |
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.